Alyeska Investment Group, L.P. Context Therapeutics Inc. Transaction History
Alyeska Investment Group, L.P.
- $23.4 Billion
- Q1 2025
A detailed history of Alyeska Investment Group, L.P. transactions in Context Therapeutics Inc. stock. As of the latest transaction made, Alyeska Investment Group, L.P. holds 1,663,355 shares of CNTX stock, worth $964,745. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,663,355
Previous 1,663,355
-0.0%
Holding current value
$964,745
Previous $1.65 Million
38.4%
% of portfolio
0.0%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding CNTX
# of Institutions
47Shares Held
79MCall Options Held
0Put Options Held
0-
Bio Impact Capital LLC Cambridge, MA14.7MShares$8.53 Million1.66% of portfolio
-
Avidity Partners Management LP Dallas, TX7.48MShares$4.34 Million1.03% of portfolio
-
Nextech Invest Ag7.42MShares$4.3 Million1.37% of portfolio
-
Nextech Invest, Ltd. Zurich, V87.42MShares$4.3 Million1.06% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.42MShares$4.3 Million0.16% of portfolio
About Context Therapeutics Inc.
- Ticker CNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,966,100
- Market Cap $9.26M
- Description
- Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therape...